Novel antibodies to a post-translational modification from CRB

Posted by & filed under Antibodies, Case Studies: Customer's publication, TARGET Antibodies: Polyclonal Antibody Production.

Christian Frezza et al. at the MRC Cancer Unit, Cambridge chose to enlist the assistance of Cambridge Research Biochemicals (CRB) to raise custom polyclonal antibodies against protein succination, a post-translational modification formed by a reaction between the tricarboxylic acid cycle intermediate fumarate with protein cysteines to form S-(2-succino)cysteine (2SC). “We contacted CRB for the generation of the 2SC… Read more »

Targeted antibodies for immunofluorescence from CRB

Posted by & filed under Antibodies, Case Studies: Customer's publication.

Gamma-tubulin ring complexes (γ-TuRCs) are highly conserved multi-protein complexes which localise to MTOCs (microtubule organising centres) in different parts of the cell at different times to influence microtubule array formation. Microtubule arrangement is essential to cell division and many other cell processes, and microtubule defects are associated with a variety of human pathologies. Paul Conduit… Read more »

When will there be a cure for Alzheimer’s Disease? An interview with Dr John Viles

Posted by & filed under Blog, Peptide Research.

Artilce by Dr Stephen Hoare. I met John Viles in December 2017 to discuss his work on protein misfolding and degenerative diseases. John is a structural biologist in the School of Biological and Chemical Sciences, Queen Mary University of London. He is interested in protein misfolding diseases, of which the main one is Alzheimer’s disease…. Read more »

Cambridge Research Biochemicals to Support Preclinical Study on Treatment for Vision-Damaging Eye Disease

Posted by & filed under News.

Under a new contract, Cambridge Research Biochemicals® will support evaluation of a potential new treatment approach for Fuchs Dystrophy, a disease that typically occurs in middle age and may cause a gradual loss of vision. Cambridge Research Biochemicals (CRB), under contract to Leidos Biomedical Research, Inc., will develop reagents to evaluate eFGF-1, a compound that… Read more »

An Interview with Cesar de la Fuente by Dr Stephen Hoare

Posted by & filed under Anti-Microbial peptides, Blog, Peptide Research, Peptide Substrates, Peptides.

Dr. Sophie Rose and I recently met Dr. César de la Fuente when he gave the opening talk at the 8th International Meeting on Antimicrobial Peptides (IMAP 2017) in Copenhagen in August 2017. César explained how he incorporates synthetic chemical biology and computational strategies as a way of redesigning antimicrobial peptides (AMPs). He believes that… Read more »

Novel Mutation Specific Antibodies

Posted by & filed under Antibodies, Blog, Case Studies: Customer's publication.

In a collaboration with Professor Richard Grundy and Dr Farhana Haque at the Children’s Brain Tumour Research Centre (CBTRC), Layfield and co-workers employed novel mutation specific antibodies generated by Cambridge Research Biochemicals to discriminate missense (G34R and G34V) mutant histone H3 (H3.3) proteins from their wild type counterparts. The antibodies generated were shown to detect… Read more »

An Interview with Dr Donald J. Davidson

Posted by & filed under Anti-Microbial peptides, Blog, Peptalk, Peptide Research, Peptides.

Antibiotic resistance is of growing concern. Antimicrobial peptides are interesting because they have the potential for treating microbial infections with less risk of resistance. Many are also involved in the innate immune system and so are also known as cationic host defence peptides. In August of this year, over 100 researchers descended on the beautiful… Read more »

Peptide-PNA conjugates distributed by Cambridge Research Biochemicals

Posted by & filed under Blog, Case Studies: Customer's publication.

Complications which arise during pregnancy are often found to be caused by a placental abnormality or malfunction, or poor placental growth and development. For these conditions, treatment is rarely available, due to the unwanted side effects of drugs and risk of birth defects in the unborn fetus. Dr Lynda K. Harris and Colleagues at the University… Read more »

CRB to licence novel fluorescent dyes with the University of Edinburgh

Posted by & filed under News.

Cambridge Research Biochemicals® (CRB), offering over 37 years of expertise in the custom supply of research reagents, namely peptides and antibodies for life science research and development, today signed a licence agreement with Edinburgh Innovations, the commercialisation arm of The University of Edinburgh. Under this new agreement, CRB will be permitted to label both custom… Read more »

CRB launches highly functional new website

Posted by & filed under News.

Cambridge Research Biochemicals (CRB), a specialist life science research tool provider based in the North East of England, today launches its brand new, much improved, user friendly website. The site, which has been re-designed and re-launched for improved customer usability and experience and incorporates new content and design features, is based around the WordPress system…. Read more »